ID   NS0-hCD20
AC   CVCL_C6XI
SY   NS/0-hCD20; NSO/CD20
DR   Wikidata; Q117704733
RX   Patent=US8329181;
RX   PubMed=26659273;
CC   Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine.
CC   Transfected with: HGNC; 7315; MS4A1.
CC   Breed/subspecies: BALB/c.
DI   NCIt; C125417; Mouse plasma cell myeloma
OX   NCBI_TaxID=10090; ! Mus musculus (Mouse)
HI   CVCL_3940 ! NS0
SX   Female
CA   Cancer cell line
DT   Created: 21-03-23; Last updated: 29-06-23; Version: 2
//
RX   Patent=US8329181;
RA   Martin J.H., Wang L.-H., Stevens S., Allison E.M.;
RT   "Methods for treating B-cell lymphoma by administering an anti-CD20
RT   antibody.";
RL   Patent number US8329181, 11-Dec-2012.
//
RX   PubMed=26659273; DOI=10.1038/srep17943;
RA   Smith E.J., Olson K., Haber L.J., Varghese B., Duramad P.,
RA   Tustian A.D., Oyejide A., Kirshner J.R., Canova L., Menon J.,
RA   Principio J., MacDonald D., Kantrowitz J., Papadopoulos N.J., Stahl N.,
RA   Yancopoulos G.D., Thurston G., Davis S.;
RT   "A novel, native-format bispecific antibody triggering T-cell killing
RT   of B-cells is robustly active in mouse tumor models and cynomolgus
RT   monkeys.";
RL   Sci. Rep. 5:17943-17943(2015).
//